Functional characterization of CYP2C8.13 and CYP2C8.14: Catalytic activities toward paclitaxel

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 1, 2010, Pages 565-569

  Hanioka, Nobumitsu ^a   Matsumoto, Kimiaki ^a   Saito, Yoshiro ^b   Narimatsu, Shizuo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C8.13; CYTOCHROME P450 2C8.14; DOCETAXEL; ISOENZYME; PACLITAXEL; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYP2C8 PROTEIN, HUMAN; UNSPECIFIC MONOOXYGENASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATALYSIS; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HYDROXYLATION; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; YEAST CELL; CHEMISTRY; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; SACCHAROMYCES CEREVISIAE;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2C8; HUMANS; HYDROXYLATION; MICROSOMES; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; SACCHAROMYCES CEREVISIAE; SUBSTRATE SPECIFICITY;

EID: 77953838981     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00543.x     Document Type: Article

References (36)

1. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996 6 : 1 42.
2. Goldstein JA, de Morais SM. Pharmacogenetics Pharmacogenetics 1994 4 : 285 299.
3. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 2008 392 : 1093 1108.
4. Gray IC, Nobile C, Muresu R, Ford S, Spurr NK. A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. Genomics 1995 28 : 328 332.
5. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005 77 : 341 352.
6. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009 10 : 1489 1510.
7. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995 275 : 566 575.
8. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999 48 : 424 432.
9. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001 11 : 597 607.
10. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001 24 : 1427 1430.
11. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002 64 : 1579 1589.
12. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002 17 : 374 377.
13. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005 33 : 630 636.
14. Saito Y, Katori N, Soyama A, Nakajima Y, Yoshitani T, Kim SR, et al. CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics 2007 17 : 461 471.
15. Sakaki T, Akiyoshi-Shibata M, Yabusaki Y, Ohkawa H. Organella-targeted expression of rat liver cytochrome P450c27 in yeast: genetically engineered alteration of mitochondrial P450 into a microsomal form creates a novel functional electron transport chain. J Biol Chem 1992 267 : 16497 16502.
16. Narimatsu S, Yonemoto R, Saito K, Takaya K, Kumamoto T, Ishikawa T, et al. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 2006 71 : 1377 1385.
17. Wan J, Imaoka S, Chow T, Hiroi T, Yabusaki Y, Funae Y. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity. Arch Biochem Biophys 1997 348 : 383 390.
18. Hichiya H, Takemi C, Tsuzuki D, Yamamoto S, Asaoka K, Suzuki S, et al. Complementary DNA cloning and characterization of cytochrome P450 2D29 from Japanese monkey liver. Biochem Pharmacol 2002 64 : 1101 1110.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951 193 : 265 275.
20. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964 239 : 2370 2378.
21. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970 227 : 680 685.
22. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979 76 : 4350 4354.
23. Imaoka S, Ogawa H, Kimura S, Gonzalez FJ. Complete cDNA sequence and cDNA-directed expression of CYP4A11, a fatty acid ω-hydroxylase expressed in human kidney. DNA Cell Biol 1993 12 : 893 899.
24. *10 might be caused not only by the low-expression but also by low affinity of CYP2D6. Arch Biochem Biophys 2000 380 : 303 308.
25. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994 54 : 5543 5546.
26. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000 28 : 1303 1310.
27. Kerdpin O, Elliot DJ, Boye SL, Birkett DJ, Yoovathaworn K, Miners JO. Differential contribution of active site residues in substrate recognition sites 1 and 5 to cytochrome P450 2C8 substrate selectivity and regioselectivity. Biochemistry 2004 43 : 7834 7842.
28. Melet A, Marques-Soares C, Schoch GA, Macherey AC, Jaouen M, Dansette PM, et al. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry 2004 43 : 15379 15392.
29. Schoch GA, Yano JK, Sansen S, Dansette PM, Stout CD, Johnson EF. Determinants of cytochrome P450 2C8 substrate binding: structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid. J Biol Chem 2008 283 : 17227 17237.
30. Schoch GA, Yano JK, Wester MR, Griffin KJ, Stout CD, Johnson EF. Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J Biol Chem 2004 279 : 9497 9503.
31. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin Pharmacokinet 2001 40 : 263 281.
32. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005 11 : 8097 8104.
33. Marsh S, Somlo G, Li X, Frankel P, King CR, Shannon WD et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J 2007 7 : 362 365.
34. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005 77 : 468 478.
35. Kirchheiner J, Thomas S, Bauer S, Tomalik-Scharte D, Hering U, Doroshyenko O, et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 2006 80 : 657 667.
36. *3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 2008 36 : 73 80.